Histopathological and Genomic Grading Provide Complementary Prognostic Information in Breast Cancer : A Study on Publicly Available Datasets

Abstract EN

The genomic grade (GG) for breast cancer is thought to be the genomic counterpart of histopathological grade (HG).

The motivation behind this study was to see whether HG retains its prognostic impact even when adjusted for GG, or whether it can be replaced by the latter.

Four publicly available gene expression datasets were analyzed.

Kaplan-Meier curves, log rank test, and Cox regression were used to study recurrence-free survival (RFS) and distant metastasis-free survival (DMFS).

HG remained a significant prognostic indicator in low GG tumors (P = 0.003 for DMFS, P< 0.001 for RFS) but not in high GG tumors.

HG grade 2 tumors differed significantly from HG grade 1 tumors, underlining the prognostic role of intermediate HG tumors.

Additionally, GG could stratify HG 1 as well as HG 2 tumors into distinct prognostic groups.

HG and GG add independent prognostic information to each other.

However, the prognostic effects of both HG and GG are time varying, with the hazard ratios of high HG and GG tumors being markedly attenuated over time.